Lithium Ion

Lithium Ion

SCHEMBL30863538

COc1cc(C(=O)[O-])ccc1N1C[C@H]2C[C@@H]1CN2C.[Li+]

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 2/20 0.39
▸ HSD11B1 P28845 1/20 0.38
▸ KMT2A Q03164 1/20 0.37
▸ BRAF P15056 1/20 0.36
▸ PKM P14618 1/20 0.35
▸ CNR2 P34972 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ KCNH2 Q12809 2/20 0.34
▸ CHRNA7 P36544 1/20 0.34
▸ MAP4K1 Q92918 1/20 0.34
▸ EGFR P00533 1/20 0.34
▸ KDM2B Q8NHM5 1/20 0.33
▸ HTR7 P34969 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30863487 0.86 MAPT (0.45) CYP2D6KMT2APKMCNR2
SCHEMBL30863539 0.71 ABCB1 (0.45) KMT2ABRAFPKMCYP1A2CYP3A4
SCHEMBL30863472 0.71 ABCB1 (0.45) KMT2ABRAFPKMCYP1A2CYP3A4
Veratric Acid SCHEMBL3779939 0.69 TSHR (0.68) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL18186207 0.67 HDAC1 (0.45) HSD11B1
SCHEMBL18186327 0.66 HSD11B1 (0.43) HSD11B1KMT2APKM
Vanillic Acid SCHEMBL8853970 0.66 MEN1 (0.70) KMT2ACYP1A2
Veratric Acid SCHEMBL9513119 0.66 TSHR (0.68) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL16302065 0.64 HDAC6 (0.46) KMT2ACA1CA2KCNH2
SCHEMBL24556500 0.64 EGFR (0.38) HSD11B1KMT2ACYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581017-A1 NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS Biodol Therapeutics (FR) 2025-07-09 — — EP disclosed
WO-2024079072-A1 NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS BIODOL THERAPEUTICS (FR) 2024-04-18 — — WO disclosed
Send feedback